HER2+ Breast Cancer

Katherine D. Crew, MD, MS, discusses recent advances made in HER2-positive breast cancer treatment.

Sara M. Tolaney, MD, MPH, discusses sequencing strategies in metastatic HER2-positive breast cancer.

Anne Favret, MD, discusses the evolution of treatment in HER2-positive breast cancer.

Global access to neratinib has increased with the drug now being made commercially available in Singapore.

Rashmi Murthy, MD, MBE, discusses the data that led to the approval of the tucatinib triplet, the clinical implications of the approval on practice, and the next steps for research with the agent.

Rashmi Murthy, MD, MBE, discusses the data that led to the approval of the tucatinib triplet, the clinical implications of the approval on practice, and the next steps for research with the agent.

Trastuzumab-dttb (Ontruzant) is now officially available for clinical use in the United States.

Stephanie L. Graff, MD, discusses genomic risk prediction in patients with hormone receptor–positive, HER2-negative breast cancer.